Retinoids are promising chemopreventive agents in animals and in humans. However, because currently available retinoids are relatively toxic, retinoids are not generally used for cancer prevention. The long-term goal of our studies is to elucidate the mechanisms by which retinoids inhibit carcinogenesis in order to develop more effective and less toxic chemopreventive agents. Our preliminary studies demonstrate that 9cRA suppresses mammary tumor development in transgenic mice, but that is also induces significant toxicity. We have also shown that pathway- selective retinoids, which may be less toxic than naturally occurring broad spectrum retinoids, can inhibit the proliferation of normal and malignant breast cells. We now propose to test the hypotheses that pathway-specific retinoids will efficiently prevent breast carcinogenesis with reduced toxicity. Firstly, we will determine whether the ability of retinoids to suppress breast tumorigenesis is dependent on the specific oncogenic pathway. We will compare the chemopreventive efficacy of 9-cis retinoic acid (9cRA) in different animal models which develop breast tumors through distinct mechanisms, such as by overexpression of the c-myc or Her2/neu genes, or by chronic estrogen exposure. We will also determine whether this broad-spectrum retinoid interferes with the progression of premalignant to malignant breast tumors in these models. Secondly, we will determine which pathway-selective retinoids are able to suppress carcinogenesis in vivo. We will compare the chemopreventive efficacy and toxicity of RAR-, RXR-, and anti-AP-1-selective retinoids with that of 9cRA in animals in which 9cRA prevents breast carcinogenesis. Thirdly, we will determine whether changes in the expression of retinoid-regulated genes involved in growth regulation are associated with successful chemoprevention by retinoids. We will investigate the retinoid-induced changes in the expression of RARbeta, E-cadherin and matrix metalloproteinase-9, all of which are involved in regulating the growth and invasiveness of breast cells. We will then determine whether changes in the expression of these markers are associated with decreased proliferation, increased apoptosis, or decreased invasiveness. Through these studies we plan to identify pathway-selective retinoids which effectively prevent mammary tumorigenesis with minimal toxicity. Such investigations will provide the foundation for the development of more specific preventive retinoids and the justification for testing such agents in clinical chemoprevention trials in humans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA078480-05
Application #
6497491
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Perloff, Marjorie
Project Start
1999-04-06
Project End
2004-01-31
Budget Start
2002-02-01
Budget End
2003-01-31
Support Year
5
Fiscal Year
2002
Total Cost
$352,756
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Uray, Iván P; Dmitrovsky, Ethan; Brown, Powel H (2016) Retinoids and rexinoids in cancer prevention: from laboratory to clinic. Semin Oncol 43:49-64
Uray, Iván P; Rodenberg, Jennifer M; Bissonnette, Reid P et al. (2012) Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor ?-dependent mechanism. Mol Pharmacol 81:228-38
Mazumdar, Abhijit; Medina, Daniel; Kittrell, Francis S et al. (2012) The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice. Cancer Prev Res (Phila) 5:1195-202
Howe, Louise R; Brown, Powel H (2011) Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila) 4:1149-57
Li, Yuxin; Shen, Qiang; Kim, Hee-Tae et al. (2011) The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor. Breast Cancer Res Treat 128:667-77
Uray, Iván P; Brown, Powel H (2011) Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res 188:147-62
Zhang, Guihong; Brewster, Abenaa; Guan, Baoxiang et al. (2011) Tumor-suppressor activity of RRIG1 in breast cancer. BMC Cancer 11:32
Brown, Powel H; Viner, Jaye L; Brewster, Abenaa et al. (2009) Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila) 2:995-8
Uray, Iván P; Shen, Qiang; Seo, Hye-Sook et al. (2009) Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 284:345-53
Li, Y; Zhang, Y; Hill, J et al. (2008) The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer 98:1380-8

Showing the most recent 10 out of 23 publications